Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab versus placebo with corticosteroid tapering in polymyalgia rheumatica
MOH_2019-04-08_006006Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Sarilumab + 14-week corticosteroid taper with Placebo + 52-week corticosteroid taper (2 arms). Started Jan 2019; status: recruiting.
02
Drugs
sarilumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on MOH_2019-04-08_006006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-08_006006.